Introduction and objective: One of the greatest challenges of modern medicine, both in the clinical, economic and social aspects, is the care of pa-tients with chronic heart failure. It is estimated that currently this problem affects about 0.83% of the world's population. The significant progress that has been made over the last decades in the diagnosis of patients with heart failure with reduced ejection fraction (HFrEF) as well as patients with heart failure with preserved ejection fraction (HFpEF) leads to a linear increase in the number of patients with heart failure. Paradoxically, despite the progress in treatment, the pro-spects for this group of patients are still unfavorable, significantly exceeding the mortality rate in cancer diseases. What's already known about this topic?: Heart failure with preserved ejection fraction HFpEF associated with obesity and sleep – related breathing disorders (SBD) is currently one of the most common phenotypes in developed countries. Moreover, cognitive impairment (CI) is observed in approximately 25-50% of patients with HFpEF. This is particularly important in the field of behavioral abilities disorders, such as the ability to remember, distinguish objects, and learn. Therefore, a very important aspect in the care of patients with HFpEF is the speed of diagnosing cardiac dysfunction and early diagnosis of mild cognitive impairment (MCI) in the preclinical phase. Early implementation of appropriate therapies can both prevent the occurrence of demen-tia, restore normal cognitive functions, and, by inhibiting the progression of cognitive disorders (by improving self-care, adherence to recommendations, etc.), have a positive impact on the course of heart failure itself. Abstract: The sodium-glucose co-transporter 2 inhibitor (SGLT2-I) show significant cardiovascular benefits (cardiovascular events, cardiovascular mortality, frequency of hospitalization due to HF) and in terms of cognitive dysfunction.